Benzinga | Jan 3, 2022 10:12AM EST

What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish BearishTotal Ratings 3 5 1 0 0Last 30D 0 1 0 0 01M Ago 0 0 0 0 02M Ago 2 1 0 0 03M Ago 1 3 1 0 0

In the last 3 months, 9 analysts have offered 12-month price targets for Alnylam Pharmaceuticals. The company has an average price target of $209.67 with a high of $273.00 and a low of $108.00.

Below is a summary of how these 9 analysts rated Alnylam Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This average price target has increased by 15.11% over the past month.

Analyst Ratings: What Are They?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.